Latest News and Press Releases
Want to stay updated on the latest news?
-
PHILADELPHIA, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) – Class Action Survives Motion to Dismiss: Grabar Law Office is investigating claims on behalf of...
-
PHILADELPHIA, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) – Class Action Survives Motion to Dismiss: Grabar Law Office is investigating claims on behalf of...
-
PHILADELPHIA, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) – Class Action Survives Motion to Dismiss: Grabar Law Office is investigating claims on behalf of...
-
PHILADELPHIA, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) – Class Action Survives Motion to Dismiss: Grabar Law Office is investigating claims on behalf of...
-
PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) – Class Action Survives Motion to Dismiss: Grabar Law Office is investigating claims on behalf of...
-
PHILADELPHIA , Oct. 13, 2025 (GLOBE NEWSWIRE) -- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) – Class Action Survives Motion to Dismiss: Grabar Law Office is investigating claims on behalf of...
-
PHILADELPHIA, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) – Class Action Survives Motion to Dismiss: Grabar Law Office is investigating claims on behalf of...
-
PHILADELPHIA, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX): Grabar Law Office is investigating claims on behalf of shareholders of Amylyx Pharmaceuticals, Inc....